FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

FDA’s approval of Lynparza for pancreatic cancer notches a trio of firsts: the first drug approved for the indication based on PFS rather than OS, the first PARP inhibitor approved to treat the disease, and the first in pancreatic cancer targeted to a molecular subgroup of patients.

FDA approved Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) as maintenance therapy of germline BRCA-mutated metastatic pancreatic cancer in patients who have not progressed on platinum chemotherapy. The agency also approved BRACAnalysis CDx from Myriad Genetics Inc. (NASDAQ:MYGN) as a companion diagnostic...